Sen­a­tor turns up heat on in­haler man­u­fac­tur­ers to re­move im­prop­er­ly list­ed Or­ange Book patents

Sen. Tam­my Bald­win (D-WI) is the lat­est law­mak­er to call on in­haler man­u­fac­tur­ers to re­move what the FTC has deemed im­prop­er­ly list­ed patents from the Or­ange Book as pol­i­cy­mak­ers con­tin­ue to pres­sure phar­ma com­pa­nies for mis­us­ing the patent sys­tem to fend off com­pe­ti­tion.

In let­ters to As­traZeneca, Boehringer In­gel­heim, GSK and Te­va on Tues­day, Bald­win urged the com­pa­nies to re­move patents that the FTC iden­ti­fied in No­vem­ber as be­ing im­prop­er­ly list­ed and staving off gener­ic and biosim­i­lar com­pe­ti­tion. The let­ter echoes the com­plaints of Sen. Amy Klobuchar (D-MI), who sent let­ters to six in­haler man­u­fac­tur­ers, in­clud­ing the four tar­get­ed by Bald­win, ear­li­er this month ask­ing them to com­ply with the FTC’s re­quest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER